Literature DB >> 19336011

Progress in the treatment of neuroendocrine tumors.

Jennifer A Chan1, Matthew H Kulke.   

Abstract

Traditional treatments for patients with advanced neuroendocrine tumors include surgical debulking, hepatic embolization, somatostatin analogues, and interferon-alpha. Patients with pancreatic neuroendocrine tumors also may benefit from treatment with the alkylating agents streptozocin or temozolomide. In recent years, several promising new approaches have been investigated in patients with advanced neuroendocrine tumors. One such approach has been the use of radiopeptide therapy targeting somatostatin receptors. Additionally, agents targeting the vascular endothelial growth factor pathway and mammalian target of rapamycin have shown preliminary evidence of activity and are currently being evaluated in large randomized studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19336011      PMCID: PMC4029419          DOI: 10.1007/s11912-009-0028-0

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  44 in total

Review 1.  Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives.

Authors:  W A Breeman; M de Jong; D J Kwekkeboom; R Valkema; W H Bakker; P P Kooij; T J Visser; E P Krenning
Journal:  Eur J Nucl Med       Date:  2001-09

2.  Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results.

Authors:  Christian Loewe; Martin Schindl; Manfred Cejna; Bruno Niederle; Johannes Lammer; Siegfried Thurnher
Journal:  AJR Am J Roentgenol       Date:  2003-05       Impact factor: 3.959

3.  Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.

Authors:  D O'Toole; M Ducreux; G Bommelaer; J L Wemeau; O Bouché; F Catus; J Blumberg; P Ruszniewski
Journal:  Cancer       Date:  2000-02-15       Impact factor: 6.860

4.  Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282.

Authors:  R K Ramanathan; A Cnaan; R G Hahn; P P Carbone; D G Haller
Journal:  Ann Oncol       Date:  2001-08       Impact factor: 32.976

Review 5.  Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.

Authors:  Marion De Jong; Roelf Valkema; Francois Jamar; Larry K Kvols; Dik J Kwekkeboom; Wout A P Breeman; Willem H Bakker; Chuck Smith; Stanislas Pauwels; Eric P Krenning
Journal:  Semin Nucl Med       Date:  2002-04       Impact factor: 4.446

6.  Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies.

Authors:  Lowell B Anthony; Eugene A Woltering; Gregory D Espenan; Michele D Cronin; Tom J Maloney; Kevin E McCarthy
Journal:  Semin Nucl Med       Date:  2002-04       Impact factor: 4.446

7.  In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial.

Authors:  Irene Virgolini; Keith Britton; John Buscombe; Roy Moncayo; Giovanni Paganelli; Pietro Riva
Journal:  Semin Nucl Med       Date:  2002-04       Impact factor: 4.446

8.  Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features.

Authors:  Stefano La Rosa; Silvia Uccella; Giovanna Finzi; Luca Albarello; Fausto Sessa; Carlo Capella
Journal:  Hum Pathol       Date:  2003-01       Impact factor: 3.466

9.  Differential expression of the PTEN tumor suppressor protein in fetal and adult neuroendocrine tissues and tumors: progressive loss of PTEN expression in poorly differentiated neuroendocrine neoplasms.

Authors:  Luoquan Wang; Ana Ignat; Constantine A Axiotis
Journal:  Appl Immunohistochem Mol Morphol       Date:  2002-06

10.  Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.

Authors:  James C Yao; Alexandria T Phan; David Z Chang; Robert A Wolff; Kenneth Hess; Sanjay Gupta; Carmen Jacobs; Jeannette E Mares; Andrea N Landgraf; Asif Rashid; Funda Meric-Bernstam
Journal:  J Clin Oncol       Date:  2008-09-10       Impact factor: 44.544

View more
  15 in total

1.  NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas.

Authors:  Matthew H Kulke; Lowell B Anthony; David L Bushnell; Wouter W de Herder; Stanley J Goldsmith; David S Klimstra; Stephen J Marx; Janice L Pasieka; Rodney F Pommier; James C Yao; Robert T Jensen
Journal:  Pancreas       Date:  2010-08       Impact factor: 3.327

2.  Radiotherapy: Radioactive somatostatin analog therapy against carcinoids.

Authors:  Run Yu
Journal:  Nat Rev Endocrinol       Date:  2010-08       Impact factor: 43.330

3.  Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years' Assessment.

Authors:  Mohammadali Hamiditabar; Muzammil Ali; Joseph Roys; Edward M Wolin; Thomas M OʼDorisio; David Ranganathan; Izabela Tworowska; Jonathan R Strosberg; Ebrahim S Delpassand
Journal:  Clin Nucl Med       Date:  2017-06       Impact factor: 7.794

4.  Gene Amplifications in Well-Differentiated Pancreatic Neuroendocrine Tumors Inactivate the p53 Pathway.

Authors:  Wenwei Hu; Zhaohui Feng; Ippolito Modica; David S Klimstra; Lin Song; Peter J Allen; Murray F Brennan; Arnold J Levine; Laura H Tang
Journal:  Genes Cancer       Date:  2010-05-15

Review 5.  Non-functional pancreatic neuroendocrine tumor as an incidentaloma--a case report and review of literature.

Authors:  Tarun Rustagi; Mridula Rai; Frank Bauer
Journal:  J Gastrointest Cancer       Date:  2013-09

Review 6.  Histopathological, immunohistochemical, genetic and molecular markers of neuroendocrine neoplasms.

Authors:  Georgios Kyriakopoulos; Vasiliki Mavroeidi; Eleftherios Chatzellis; Gregory A Kaltsas; Krystallenia I Alexandraki
Journal:  Ann Transl Med       Date:  2018-06

Review 7.  Update in the Therapy of Advanced Neuroendocrine Tumors.

Authors:  Inbal Uri; Shani Avniel-Polak; David J Gross; Simona Grozinsky-Glasberg
Journal:  Curr Treat Options Oncol       Date:  2017-11-16

Review 8.  Advances in the therapy of gastroenteropancreatic-neuroendocrine tumours (GEP-NETs).

Authors:  Enrique Grande; Juan José Díez; Vanessa Pachón; Alfredo Carrato
Journal:  Clin Transl Oncol       Date:  2010-07       Impact factor: 3.405

9.  Predictors of response to radio-embolization (TheraSphere®) treatment of neuroendocrine liver metastasis.

Authors:  Mohammed Shaheen; Mazen Hassanain; Murad Aljiffry; Tatiana Cabrera; Prosanto Chaudhury; Eve Simoneau; Nuttawut Kongkaewpaisarn; Ayat Salman; Juan Rivera; Mohammad Jamal; Robert Lisbona; Azzam Khankan; David Valenti; Peter Metrakos
Journal:  HPB (Oxford)       Date:  2011-11-14       Impact factor: 3.647

10.  Rectal and anal canal neuroendocrine tumours.

Authors:  Teresa Raposo André; Margarida Brito; João Geraldes Freire; António Moreira
Journal:  J Gastrointest Oncol       Date:  2018-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.